首页 News 正文

Company Review | BeiGene has suffered continuous losses in the past 7 years, and its stock price is under pressure. Can the new CFO bring a turning point?

123458071
1274 0 0

On August 7th, BeiGene (SH688235, stock price 140.88 yuan, market value 193.9 billion yuan) released its financial report for the first half of 2024, with a total operating revenue of 11.996 billion yuan, a year-on-year increase of 65.4%. However, its net profit attributable to shareholders and net profit after deducting non profits were respectively 2.877 billion yuan and 3.125 billion yuan.
It is worth noting that BeiGene has suffered continuous losses in the past 7 years, with a cumulative undistributed profit of approximately 57.69 billion yuan at the end of 2023, which undoubtedly brings enormous financial pressure to the company's future development. Since its listing on the A-share market in December 2021, BeiGene's stock price performance has been unsatisfactory. The current stock price has fallen by nearly 30% compared to the issue price. The continuous decline in the company's stock price reflects investors' doubts about BeiGene's future profitability. Faced with sustained losses and declining stock prices, the company needs to find effective profit models and cost control measures while maintaining research and development investment.
In addition, the recent high-level changes in the company have also attracted market attention. The departure of Chief Financial Officer Wang Aijun and the succession of Aaron Rosenberg may have an impact on the company's financial management and strategic decision-making. Wang Aijun has extensive financial experience in the biotechnology, pharmaceutical, medical equipment, diagnostic systems, and consumer goods industries. The new CFO Rosenberg's years of work experience at Merck, particularly in capital markets and fund management, may bring new financial management strategies to BeiGene.
The future development of BeiGene is full of challenges, but the addition of the new CFO and the growth in product sales have brought new hope to the company. The market expects BeiGene to make breakthroughs in the field of innovative drugs and achieve sustainable profit growth.
When considering the investment value of BeiGene, investors should closely monitor the company's research and development progress, product market performance, and changes brought about by the new CFO. At the same time, the company's management needs to present a clear strategic plan and profit path to the market in order to rebuild investor confidence.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  •   知名做空机构香橼研究(Citron Research)周四(11月21日)在社交媒体平台X上发布消息称,该公司已决定做空“比特币大户”微策略(Microstrategy)这家公司,并认为该公司已经将自己变身成为一家比特币投资基金 ...
    caffycat
    昨天 11:18
    支持
    反对
    回复
    收藏
  •   每经AI快讯,11月20日,文远知行宣布旗下自动驾驶环卫车S6与无人扫路机S1分别在新加坡滨海湾海岸大道与滨海艺术中心正式投入运营。据介绍,这是新加坡首个商业化运营的自动驾驶环卫项目。 ...
    star8699
    3 天前
    支持
    反对
    回复
    收藏
  •   上证报中国证券网讯(记者王子霖)11月20日,斗鱼发布2024年第三季度未经审计的财务报告。本季度斗鱼依托丰富的游戏内容生态,充分发挥主播资源和新业务潜力,持续为用户提供高质量的直播内容及游戏服务,进一步 ...
    goodfriendboy
    3 天前
    支持
    反对
    回复
    收藏
  •   人民网北京11月22日电 (记者栗翘楚、任妍)2024广州车展,在新能源汽车占据“半壁江山”的同时,正加速向智能网联新能源汽车全面过渡,随着“端到端”成为新宠,智能驾驶解决方案成为本届广州车展各大车企竞 ...
    3233340
    昨天 17:06
    支持
    反对
    回复
    收藏
123458071 新手上路
  • 粉丝

    0

  • 关注

    0

  • 主题

    3